Results 181 to 190 of about 1,541,253 (387)

Structure of a naturally occurring antagonist of dihydrostreptomycin [PDF]

, 1956
J. W. Cornforth, A. T. James
openalex   +1 more source

Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome

Science, 2006
J. Habashi, D. Judge, Tammy M. Holm, R. Cohn, B. Loeys, T. Cooper, Loretha A Myers, E. C. Klein, Guosheng Liu, C. Calvi, Megan Podowski, E. Neptune, M. Halushka, D. Bedja, K. Gabrielson, D. Rifkin, L. Carta, F. Ramirez, D. Huso, H. Dietz   +19 more
semanticscholar   +1 more source

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

Molecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva, Bernardo Orr, Ana Azeredo, Andreia Brandão, Manuel R. Teixeira, Paula Paulo   +5 more
wiley   +1 more source

ANTAGONISTIC GROWTH PRINCIPLES OF SERUM AND THEIR RELATION TO OLD AGE [PDF]

, 1923
Alexis Carrel, Albert H. Ebeling
openalex   +1 more source

Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models

Molecular Oncology, EarlyView.
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon, Moa Stenudd, Margherita Zamboni, Kanar Alkass, Carl‐Johan Eriksson, Lars Pedersen, Alrik Schörling, Anna Thoss, Anders Bergh, Pernilla Wikström, Hans‐Olov Adami, Henrik Toft Sørensen, Henrik Druid, Jonas Frisén   +13 more
wiley   +1 more source

TUBERCULOSIS AND LEPROSY: MUTUALLY ANTAGONISTIC DISEASES

, 1953
R Chaussinand
openalex   +1 more source

Observations on the effects of the folic acid antagonists, aminopterin and amethopterin, in patients with advanced neoplasms [PDF]

, 1952
Emanuel B. Schoenbach, Jacob Colsky, Ezra M. Greenspan   +2 more
openalex   +1 more source

SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

FEBS Letters, 1994
M. Rinaldi-Carmona, F. Barth, M. Héaulme, D. Shire, B. Calandra, Christian Congy, Serge Martinez, J. Maruani, G. Néliat, D. Caput, P. Ferrara, P. Soubrié, J. Breliere, G. Le Fur   +13 more
semanticscholar   +1 more source

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

Molecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková, Marie Ehrlichová, Alžběta Spálenková, Ivona Krus, Simona Šůsová, Viktor Hlaváč, Vlasta Němcová, Renata Koževnikovová, Markéta Trnková, David Vrána, Jiří Gatěk, Kateřina Kopečková, Marcela Mrhalová, Soňa Měšťáková, Pavel Souček   +14 more
wiley   +1 more source

ACETYLCHOLINE ANTAGONISTS: A COMPARISON OF THEIR ACTION IN DIFFERENT TISSUES [PDF]

, 1948
F. J. De Elio
openalex   +1 more source